Sai Life Sciences Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/7vf4ju6ojcvh4m1c3avdkjsf.pdf

Key Takeaways


Demand Environment & Supply-Chain Diversification

Krishna Kanumuri: "I think pharma has made a long-term decision to kind of diversify from China. It's just a question of customer concentration. I think this deleveraging started back in post-COVID. I think Biosecure probably just pushed it in the right direction. I think nobody seems to be going any slower."

Financial Performance & Margin Walk


Capacity, Capex & the Investment Cycle

Siva Chittor: "If you do not invest in the shorter term, our overall growth rate over long term will suffer. While we will be able to continue to show a better ROCE, we will not be able to show growth and revenue on a consistent basis."

Discovery Business & Biotech Funding

Krishna Kanumuri: "Time frame is hard to judge. It's your guess as good as mine in terms of when new Company formation is going to start."

Pipeline & Commercialization


Guidance & Commitments

CommitmentSpecificsTimeline
Long-term revenue CAGR15–20% CAGROver 3–5 year blocks
EBITDA margin target28–30% steady stateNext 2–3 years
ROCE aspirationMid to high teensOver 3–4 year period
Capacity additionAnother 100 KL manufacturing capacityQ1 FY26
Q4 FY25 capexAdditional ₹100–125 crQ4 FY25
CommercializationCouple of products based on PDUFA datesBy end of FY25
CommercializationOne large Phase 3 moleculeFY26–27 timeframe
15–20% CAGR baselineCan be factored from FY26 onwardsFY26 onwards

Key Metrics

MetricQ3 FY25
Revenue from operations₹440 cr, +15% YoY vs ₹384 cr in Q3 FY24
CDMO revenue share60% of total revenue
CRO revenue share40% of total revenue
EBITDA margin28%, up from 27% in Q3 FY24, +110 bps YoY
Profit after tax₹54 cr, +36% YoY vs ₹40 cr in Q3 FY24
Profit before tax₹72 cr, +35% YoY vs ₹53 cr in Q3 FY24
Earnings per share₹2.9, +32% YoY vs ₹2.2 in Q3 FY24
Employee cost₹133 cr, +9% YoY vs ₹122 cr in Q3 FY24
Finance costs₹23 cr, stable vs ₹23 cr in Q3 FY24
9M FY25 total income₹1,142 cr, +9% YoY vs ₹1,052 cr
9M FY25 EBITDA margin24%, +700 bps YoY vs 17%
9M FY25 gross margin~73%, up from 69% in prior period
9M FY25 operating cash flow₹246 cr, 92% of EBITDA for the period
9M FY25 free cash flow₹21 cr positive
9M FY25 capex₹300 cr
Average capacity utilization (9M FY25)65%
Manufacturing capacity added100 KL in November 2024, another 100 KL expected in Q1 FY26
Discovery R&D capacity expansion15% increase in Hyderabad lab spaces
IPO debt repayment₹585 cr repaid of planned ₹720 cr as of Dec 2024, remaining repaid in January 2025
Commercial molecules supplied31 molecules
Products tech-transferred from other geographies15 products as part of supply chain diversification
Phase 3 pipeline8 to 10 products
Long-term revenue CAGR aspiration15–20% over 3–5 year blocks
Long-term EBITDA margin aspiration28–30%, expected in 2–3 years
Long-term ROCE aspirationMid to high teens over 3–4 years